Rigel Pharmaceuticals

Research Rigel Pharmaceuticals (RIGL) on Bullrun: valuation model: 387.0% undervalued, market cap USD 722.32M, P/E 2.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRIGL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal387.0% undervalued
• Market capUSD 722.32M
• P/E2.1
• Financial periodFY2025
• RevenueUSD 294.28M
• Revenue growth64.1%
• Net incomeUSD 367.02M
• Gross margin93.3%

Valuation Snapshot

Bullrun's latest valuation model marks Rigel Pharmaceuticals as 387.0% undervalued; latest market cap is USD 722.32M; P/E is 2.1.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia;

Frequently asked questions

Is Rigel Pharmaceuticals overvalued or undervalued?

Bullrun's valuation model currently marks Rigel Pharmaceuticals as 387.0% undervalued.

What is Rigel Pharmaceuticals's market cap?

Rigel Pharmaceuticals's market capitalization is USD 722.32M.

What is Rigel Pharmaceuticals's P/E ratio?

Rigel Pharmaceuticals's price-to-earnings (P/E) ratio is 2.1.

What does Rigel Pharmaceuticals do?

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.